NeuroVive preferential rights issue fully subscribed

NeuroVive Pharmaceutical AB (publ) has completed the preferential rights issue
of units, comprising shares and warrants, authorized by the Extraordinary
General Meeting on 31 March 2016. The preferential rights issue was 100.4 %
subscribed, raising approximately SEK 94.4 million for the company before issue
expenses. Upon full utilization of the warrants, the company will raise an
additional SEK 32.6 million. The new issue was guaranteed to 75% through
guarantee commitments. The full subscription means that underwriting guarantees
will not have to be utilized.
THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE
US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY
OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT
TO LEGAL RESTRICTIONS.

63.9 % of the preferential rights issue was subscribed for on the basis of unit
rights, and the remainder, 36.6 %, without unit rights. Overall subscription was
100.4 %, implying that available guarantees did not need to be utilized. The
preferential rights issue raises some SEK 94.4 million for the company before
issue expenses. Upon full utilization of the warrants, the company will raise an
additional SEK 32.6 million.

“We’re very satisfied with the outcome of the new issue, which shows significant
confidence in the company’s operations. It’s been extremely rewarding to meet
with existing and potential shareholders during the issue period, and I’d like
to welcome all new shareholders and thank everyone who participated in the new
issue for the trust they’ve shown in us,” commented Erik Kinnman, NeuroVive’s
CEO.

The allocation of units subscribed for without unit rights under the
preferential rights issue has taken place according to the principles indicated
in the prospectus dated 14 April 2016. Notice of allocation will be given in the
form of a transaction note sent to the relevant subscriber for allocated units.
Allocated units must be settled by no later than the date indicated on the
transaction note.

Share capital and number of shares
The new issue means that the company’s share capital will increase by SEK
899,248 through the new issue of 17,984,960 shares, each with a quotient value
of SEK 0.05.

The new issue also means that the company is issuing 2,248,120 warrants of
series 2016/2017:1, conferring the owner with the right to subscribe for a total
of 2,248,120 shares in the company, and 2,248,120 warrants of series
2016/2017:2, conferring the owner with the right to subscribe for a total of
2,248,120 shares in the company, which means that share capital may come to
increase by a total of SEK 224,812 upon full utilization of the warrants issued
of series 2016/2017:1 and series 2016/2017:2.

Trading in BTUs
Paid-up subscribed units (BTUs) under the preferential rights issue are traded
on Nasdaq Stockholm under the ticker symbol NVP BTU in the period until the new
issue has been registered with the Swedish Companies Registration Office, which
is expected to take place on or around 18 May 2016, and will subsequently be
replaced by shares and warrants. In connection with registration, the new shares
and warrants will begin to be traded on Nasdaq Stockholm.

Terms and conditions applying to warrants
One (1) warrant of series 2016/2017:1 confers the right to subscribe for one (1)
share in the company at a subscription price of SEK 6.50. Subscription for
shares in the company on the basis of warrants of series 2016/2017:1 may take
place in the period from 2 January 2017 until 28 February 2017 inclusive.

One (1) warrant of series 2016/2017:2 confers the right to subscribe for (1)
share in the company at a subscription price of 70% of the volume weighted
average price of the company’s share on Nasdaq Stockholm for 15 trading days
before the start of the subscription period, subject to a minimum of SEK 8.
Subscription for shares in the company on the basis of warrants of series
2016/2017:2 may take place in the period from 1 June 2017 until 30 June 2017
inclusive.

Advisors
Stockholm Corporate Finance AB acted as financial advisor and Advokatfirman
Lindahl KB acted as legal advisor to the company in connection with the new
issue. Aqurat Fondkommission AB acted as issuing institution in connection with
the new issue and Laika Consulting was responsible for IR and marketing.

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a
company committed to the discovery and development of highly targeted candidates
that preserve mitochondrial integrity and function in areas of significant
therapeutic need. NeuroVive’s business approach is driven by value-adding
partnerships with mitochondrial research institutions and commercial partners
across the globe. NeuroVive’s portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in
clinical and preclinical development and two drug discovery platforms. The
NeuroSTAT® product has orphan drug status in Europe and in the US for treatment
of moderate to severe traumatic brain injury and is currently being evaluated in
a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares
are listed on Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on the 10 May 2016, at 08.30 CET.

IMPORTANT INFORMATION
Publication or distribution of this press release in certain jurisdictions may
be subject to restrictions according to law and the people in jurisdictions
where this press release has been made public or distributed should inform
themselves and follow such legal restrictions. This press release does not
contain and does not constitute or form part of an invitation to acquire or
subscribe or a solicitation of any offer to buy or subscribe for shares or other
securities in NeuroVive.

This press release may not be published or distributed, directly or indirectly,
in or into the US, Australia, Hong Kong, Japan, Canada, New Zeeland, South
Africa or in any other jurisdiction where such distribution would be prohibited
by applicable law. The information in this press release may not be
redistributed, reproduced or passed on in ways that conflict with applicable
restrictions. Failure to comply with these restrictions may constitute a
violation of the United States Securities Act of 1933 or applicable laws of
other jurisdictions.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt//www.otcmarkets.com/stock/NE
V 
PF/quot)